Abstract:Background Data regarding uninterrupted oral anticoagulation in patients with chronic kidney disease (CKD) during catheter ablation for left atrial arrhythmias is limited. This study aimed to evaluate the safety and efficacy of periprocedural uninterrupted direct oral anticoagulants (DOAC) compared with uninterrupted phenprocoumon in patients with CKD undergoing left atrial catheter ablation. Methods and results We conducted a retrospective single−center study of patients who underwent left atrial catheter ablation between 2016 and 2019 with underlying chronic kidney disease (glomerular filtration rate (GFR) between 15 and 45 ml/min). The primary objective of this study was to investigate whether direct oral anticoagulant (DOAC) therapy or warfarin presents a superior safety profile in patients with chronic kidney disease (CKD) undergoing left atrial catheter ablation. We compared periprocedural complications (arteriovenous fistula, aneurysm, significant hematoma (> 5 cm)) and/or bleeding (drop in hemoglobin of >2 g/dl, pericardial effusion, retroperitoneal bleeding, other bleeding, stroke) between patients receiving either uninterrupted DOAC or warfarin therapy. Secondary analysis included patient baseline characteristics as well as procedural data. A total of 188 patients (female n = 108 (57%), mean age 75.3 ± 8.1 years, mean GFR 36.8 ± 6 ml/min) were included in this study. Underlying arrhythmias were atrial fibrillation ( n = 104, 55.3%) and atypical atrial flutter ( n = 84, 44.7%). Of these, n = 132 patients (70%) were under a DOAC medication, and n = 56 (30%) were under phenprocoumon. Major groin complications including pseudoaneurysm and/or AV fistula occurred in 8.9% of patients in the phenprocoumon group vs. 11.3% of patients in the DOAC group, which was not statistically significant ( p = 0.62). Incidence of cardiac tamponade (2.3% vs. 0%; p = 0.55) and stroke (0% vs. 0%) were low in both DOAC and phenprocoumon groups with similar post−procedural drops in hemoglobin levels (1.1±1 g/dl vs 1.1±0.9 g/dl; p = 0.71). Conclusion The type of anticoagulation had no significant influence on bleeding or thromboembolic events as well as groin complications in this retrospective study. Despite observing an increased rate of groin complications, the uninterrupted use of DOAC or phenprocoumon during left atrial catheter ablation in patients with CKD appears to be feasible and effective. Graphical This figure was created with BioRender.com.

Feasibility and safety of percutaneous epicardial access for mapping and ablation for ventricular arrhythmias in patients on oral anticoagulants

Comparison of transesophageal echocardiography findings after different anticoagulation strategies in patients with atrial fibrillation: a systematic review and meta-analysis

Periprocedural and long-term safety and feasibility of direct oral anticoagulants in patients with biological valve undergoing radiofrequency catheter ablation for atrial fibrillation: a prospective multicenter study

Renal function and periprocedural complications in patients undergoing left atrial catheter ablation: A comparison between uninterrupted direct oral anticoagulants and phenprocoumon administration

Bleeding Risks with Novel Oral Anticoagulants During Catheter Ablation of Atrial Fibrillation: a Systematic Review and Network Meta-Analysis.

Safety of Catheter Ablation of Atrial Fibrillation Without Pre‐ or Peri‐procedural Imaging for the Detection of Left Atrial Thrombus in the Era of Uninterrupted Anticoagulation

The Safety and Efficacy of Epicardial Carbon Dioxide Insufflation Compared to Conventional Epicardial Access

Real World Risk of Discontinuing Oral Anticoagulation after Successful Catheter Ablation for Atrial Fibrillation

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants versus Vitamin K Antagonist Oral Anticoagulants in Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-Analysis

Safety of Oral Anticoagulants in Perioperative Period of Ablation for Atrial Fibrillation

Risk of Stroke or Transient Ischemic Attack After Atrial Fibrillation Ablation with Oral Anticoagulant Use Guided by ECG Monitoring and Pulse Assessment

Adverse Events Requiring Hospitalization Following Catheter Ablation for Atrial Fibrillation in Heart Failure with versus without Systolic Dysfunction

Percutaneous pericardial puncture for mapping and ablation of ventricular arrhythmias: safety and efficacy

Periprocedural Acute Kidney Injury in Patients With Structural Heart Disease Undergoing Catheter Ablation of VT

“As Needed” nonvitamin K antagonist oral anticoagulants for infrequent atrial fibrillation episodes following atrial fibrillation ablation guided by diligent pulse monitoring: A feasibility study

International Incidence of Complications after Catheter Ablation of Persistent Atrial Fibrillation (af): Insights from the Multicenter, Prospective, Randomized Star Af Ii Trial

Comparison of Early Complications of Oral Anticoagulants after Totally Thoracoscopic Ablation: Warfarin versus Non-vitamin K Antagonist Oral Anticoagulants

Application of combined ablation procedures via percutaneous epi/endocardial access in patients with recurrent atrial fibrillation

Abstract 15329: Heart Failure is an Adverse Risk Factor for Peri-Procedural Complications in Patients Undergoing Pulmonary Vein Isolation and Ablation for Atrial Fibrillation

Feasibility and safety of uninterrupted apixaban in patients undergoing radiofrequency ablation for atrial fibrillation

Incidence and Outcomes of Cerebrovascular Events Complicating Catheter Ablation for Atrial Fibrillation